New Delhi: Mankind Pharma has informed in a BSE filing that a meeting of Board of Directors of the Company will be held on September 20, 2024, inter-alia to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof for an amount as may be decided by the Board.  Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products.The company in an investor presentation had stated that it looks to grow consumer healthcare business through line extensions, new launches, and premiumization, by leveraging existing brand equity, additional distribution models.Mankind also looks to increase the value of prescriptions in the existing market and increase the share of chronic segment by growing presence in existing therapies, as per the presentation.Read also: Submit Phase I/Phase II clinical trial data: CDSCO Panel Tells Mankind on Dydrogesterone Injection 5mg/mlFounded in 1991 and commenced operation in 1995, Mankind Pharma is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Read also: Mankind Pharma Vice Chairman Juneja says BSV acquisition to aid future growth of Company